Stock Markets April 22, 2026 07:12 AM

Philip Morris narrows full-year EPS outlook as nicotine pouch approvals and competition weigh

Tobacco group flags tougher rivalry from rival pouches and regulatory hesitation on Zyn while first-quarter results top estimates

By Priya Menon PM
Philip Morris narrows full-year EPS outlook as nicotine pouch approvals and competition weigh
PM

Philip Morris International trimmed its full-year adjusted earnings-per-share outlook amid mounting competition in nicotine pouch products and regulatory uncertainty surrounding its Zyn line. The company reported first-quarter revenue and adjusted EPS above consensus and said it had incorporated limited impacts from the Middle East conflict into its forecast.

Key Points

  • Philip Morris trimmed its full-year adjusted EPS outlook to $8.36-$8.51 from $8.38-$8.53.
  • First-quarter revenue of $10.15 billion and adjusted EPS of $1.96 beat consensus estimates.
  • Competitive pressure from rivals like British American Tobacco's Velo and regulatory delays for Zyn pouches are weighing on the company's outlook; impacts from the Middle East conflict have been included but are not expected to be prolonged.

April 22 (Reuters) - Philip Morris International lowered its full-year profit guidance on Wednesday, pointing to intensified competition in the nicotine pouch market and lingering regulatory uncertainty over its Zyn product family. The company, which markets Marlboro outside the United States, has been increasing investment to move beyond combustible cigarettes, but is encountering fierce rivalry from other pouch brands such as British American Tobacco's Velo and delays in approval for new Zyn variants.

Philip Morris said it now anticipates adjusted earnings per share for the full year in a range of $8.36 to $8.51, compared with its earlier forecast of $8.38 to $8.53. The updated outlook reflects the company’s assessment of competitive pressures and the regulatory environment for its alternative nicotine products.

On the regulatory front, popular nicotine pouch products have not yet been cleared for sale in the U.S. despite a fast-track Food and Drug Administration scheme. Agency scientists have expressed hesitancy about authorizing some products because of concerns about potential uptake among new users, including children, Reuters reported earlier this month. Philip Morris said it has included effects from the Middle East conflict in its planning but does not anticipate those effects to be prolonged.

For the first quarter, Philip Morris reported revenue of $10.15 billion, ahead of analysts’ average expectation of $9.91 billion compiled by LSEG. Quarterly adjusted earnings were $1.96 per share, beating the $1.83-per-share estimate.

The company has intensified spending to broaden its portfolio beyond traditional cigarettes while navigating a tougher competitive landscape in nicotine pouches. That strategic shift is taking place against the backdrop of FDA deliberations that have slowed market access for some pouch products in the United States.

Industry observers and investors will be watching how quickly Philip Morris can convert its investments into revenue streams that offset pressure on cigarette volumes and respond to competitive moves from rival pouch makers. The company's current guidance incorporates near-term geopolitical considerations and regulatory uncertainty but leaves open the possibility of future adjustments depending on market and approval developments.

Should you invest $2,000 in PM right now? ProPicks AI evaluates PM alongside thousands of other companies every month using more than 100 financial metrics. The tool applies artificial intelligence to screen fundamentals, momentum, and valuation without bias, identifying stocks it deems to offer attractive risk-reward profiles. The item noted recent notable winners in its selections and invited readers to check whether PM appears in its strategies or whether there are other opportunities in the same sector. Flash Sale - Price Goes Up Soon

Risks

  • Regulatory uncertainty around FDA authorization of nicotine pouch products could delay U.S. market entry and affect revenue growth - this risk impacts consumer staples and tobacco sectors.
  • Intensifying competition in nicotine pouches from brands such as Velo may pressure market share and margins for Philip Morris - this affects the tobacco and consumer-packaged-goods sectors.
  • Geopolitical developments in the Middle East present a potential near-term headwind; while the company does not expect prolonged effects, ongoing instability could affect operations or supply chains in affected markets - this risk touches industrials and global consumer markets.

More from Stock Markets

Robinhood Ventures Allocates $75M to OpenAI as Part of Push into Private Markets Apr 22, 2026 Executives, trusts and major holders disclose big stock moves; Astera Labs CEO sells $57.85M Apr 22, 2026 Limited-Time InvestingPro Offer Cuts Price to Under $7 a Month on Selected Plans Apr 22, 2026 Upstart Secures $1.2 Billion Forward-Flow Commitment from Centerbridge, Shares Rise Apr 22, 2026 Tadawul All Share Falls 0.88% as Media, Agriculture and Energy Stocks Lead Decline Apr 22, 2026